ArticleNature medicine2019
Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.Expert review of clinical pharmacology · 2020Pooled it
- Integrated pan-cancer analysis reveals a cancer-associated fibroblast oxidative stress response signature predicting immunotherapy response and prognosis.Apoptosis : an international journal on programmed cell death · 2026Article
- Multi-omics analysis reveals AR as a potential prognostic factor and immune-related therapeutic target in gastric cancer.Biochemistry and biophysics reports · 2026Article
- Integrative multi-omics analysis reveals an 11-gene malignant-myeloid interaction signature and identifies TPST1 as a potential regulator of immunosuppressive microenvironment in glioma.Discover oncology · 2026Article
- Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors.Cancer biology & medicine · 2026Article
- Mismatch Repair Deficiency in Gliomas: A Rare Insight into Microsatellite Instability and Its Diagnostic Implications.Asian journal of neurosurgery · 2025Article
- Article
- LIMK1 is a prognosis and treatment biomarker in hepatocellular carcinoma.Scientific reports · 2025Article
- Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma.Journal of clinical & translational endocrinology · 2025Article
- Comprehensive Characterization of the Immune Microenvironment Based on Nested Resampling Machine Learning Framework Identifies TRAF3 Interacting Protein 3 as a Promising Regulator to Improve the Resistance to Immunotherapy in Glioma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Understanding and overcoming resistance to immunotherapy in genitourinary cancers.Cancer biology & therapy · 2024Review
- Multi-omics profiling highlights karyopherin subunit alpha 2 as a promising biomarker for prognosis and immunotherapy respond in pediatric and adult adrenocortical carcinoma.Annals of medicine · 2024Article
- Article
- Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response.NPJ precision oncology · 2024Article
- Machine learning-based investigation of regulated cell death for predicting prognosis and immunotherapy response in glioma patients.Scientific reports · 2024Article
- Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment.Frontiers in immunology · 2024Article
- Review
- PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma.Journal of neuro-oncology · 2022Article
- Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity.Frontiers in oncology · 2022Review
- Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?Neuro-oncology · 2021Article
Corrections and comments
- Erratum for
Authors and funding
27 authors.
Funding
Abstract
In the version of this article originally published, the graph in Extended Data Fig. 2c was a duplication of Extended Data Fig. 2b. The correct version of Extended Data Fig. 2c is now available online.
Identifiers
30996326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.